The number of clinical trials starting in Serbia is returning to pre-pandemic levels, but the context in which these studies are operating has changed. The impact of COVID-19 demonstrated the limitations of the direct-to-site logistics model, when supply chains were distributed due to travel and transport restrictions, which in turn affected trial data collection, resupply and most importantly patient treatment.
In-country storage can help to protect your clinical trial supply chain against future disruption, and improve efficiency which ultimately reduces time and associated costs.
At Oximio, we have used our experience of Balkan clinical trials to compile a short report on the Serbian market, including an update the dynamics and the main study stakeholders.
Could logistics redesign help to secure your supply chain? Download the report to find out more.
